THCA Therapeutics adopted an asset-light biotechnology development model centered on collaboration with GMP-certified Contract Development and Manufacturing Organizations (CDMOs). This strategy enables scalable pharmaceutical manufacturing while allowing the company to remain focused on scientific innovation and clinical development.